Blog

Development of a targeted FAST-LNP formulation of cabazitaxel to improve efficacy and safety for prostate cancer treatment

NMIN Funded Theme I Project in Targeted Drug Delivery

NMIN Funded Theme I Project in Targeted Drug Delivery
Development of a targeted FAST-LNP formulation of cabazitaxel to improve efficacy and safety for prostate cancer treatment
PI: John D. Lewis (University of Alberta)
Co-Investigators: Roy Duncan (Dalhousie University)
Collaborators: Arun Raturi (Entos Pharmaceuticals), Michael Kolinski (University of Alberta), Adrian Fairey (University of Alberta)
HQP: Konstantin Stoletov, Maryam Hejazi, Douglas Brown
Partners: APCaRI, Entos Pharmaceuticals, OncoSenX, Precision Nanosystems
Status: Active – funding cycle: 2020-2022

In this project, we propose to encapsulate the small molecule cabazitaxel in FAST-liposomes and assess the incorporation of ligand-directed targeting to cancer-specific receptors to improve efficacy and safety.

Taxane chemotherapies such as Cabazitaxel are currently approved for several solid tumours including prostate cancer, and this project will seek to improve their side-effect profile to further improve efficacy.

Successful implementation of the outputs of this project will have significant positive academic, social and economic impacts. Industry partners including Entos Pharmaceuticals, OncoSenX, Precision Nanosystems; academic partners such as the University of Alberta, the Alberta Prostate Cancer Research Initiative (APCaRI), the University of British Columbia, and the NMIN Network; and healthcare and patient stakeholders will benefit from the development of a well-tolerated, non-immunogenic, targeted delivery platform for oncology chemotherapy drugs such as cabazitaxel to prostate, breast and pancreatic cancers.

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Recent Posts

goes to...APCaRI member Russ Greiner Posted on Jun 15 21 at 7:51pm
Participation Milestone! Posted on May 29 21 at 6:12pm
Raja Singh Posted on Apr 30 21 at 12:24pm

Raja Singh

Raja Singh

APCaRI welcomes our new Director, Raja B. Singh who brings a wealth of precision health networking expertise to APCaRI.
With over 12 years of experience in innovation, commercialization, and translational research, Raja has helped Canadian collaborative researchers and clinicians translate novel research from bench to market. We are excited to have Raja on board!

 

Catalina Vasquez

APCaRI also sends thanks to outgoing Interim Director Catalina Vasquez for her dedication and service to APCaRI. Catalina worked tirelessly with APCaRI researchers, clinicians, funders, and patients to help shape APCaRI into what it is today. We greatly appreciate her commitment to improving the lives of Albertan patients and their families and her continued commitment to improving the outcomes of cancer patients.

- Perrin Beatty